Use of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor for treatment and/or prevention of coxsackievirus infection and adenoviral infection or diseases caused by coxsackievirus and/or adenovirus e.g. myocarditis and pericarditis

摘要

Use of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor for the treatment and/or prevention of coxsackievirus infection and adenoviral infection, or diseases caused by coxsackievirus and/or adenovirus, is claimed. An independent claim is also included for a pharmaceutical composition comprising at least one HMG-CoA reductase inhibitor. ACTIVITY : Cardiant; Antiinflammatory; Neuroprotective; Gastrointestinal-Gen; Ophthalmological; Antiallergic; Respiratory-Gen; Antidiarrheic; Cytostatic; Virucide. MECHANISM OF ACTION : HMG-CoA reductase inhibitor. The ability of lovastatin (HMG-CoA reductase inhibitor) to reduce the concentration of coxsackie-adenovirus receptor (CAR) mRNA expression was tested in human umbilical vein endothelial cells. The results showed that lovastatin at a concentration of 5 mu M decreases the concentration of CAR mRNA expression by 76%.